Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Carcinoma, Hepatocellular 29Neoplasms 18Neoplasm Metastasis 14Melanoma 14Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Nasopharyngeal Carcinoma 10Esophageal Squamous Cell Carcinoma 10Triple Negative Breast Neoplasms 9Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Breast Neoplasms 8Rectal Neoplasms 7Pancreatic Neoplasms 7Lung Neoplasms 7Carcinoma, Renal Cell 7Biliary Tract Neoplasms 7Small Cell Lung Carcinoma 6Colonic Neoplasms 5Cholangiocarcinoma 5Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3

Interventions

Influenza Vaccines 16trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2Vaccines 2Oseltamivir 2FluMist 2Cyclophosphamide 2ziprasidone 1vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Starch 1Spironolactone 1Sevelamer 1SARS-CoV-2 inactivated vaccines 1Rocuronium 1Rituximab 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nivolumab 1Nifedipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Influenza, Human × Immune Checkpoint Inhibitors × Clear all
NCT04355806 2020-04-21

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Shanghai Pulmonary Hospital, Shanghai, China

Unknown
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Influenza, Human

Data powered by HemOnc (CC BY 4.0) Colophon âš¡